Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The hypothesis underlying this study is that nasally administered calcitonin will stabilize
or improve bone mineral density in young patients with ulcerative colitis or Crohn's disease.
Patients who participate will receive either calcitonin or placebo and will have their bone
mineral density measured at the start, at nine months, and at 18 months of study.
Participants will also receive age appropriate doses of vitamin D and calcium supplements.
Other serological measures of vitamin D status will be obtained every 3 months during the
study.
Phase:
N/A
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital
Collaborators:
Crohn's and Colitis Foundation National Institutes of Health (NIH)